Advanced nanoformulations against bacterial infection

Q Pharmacology, Toxicology and Pharmaceutics Anales De La Real Academia Nacional De Farmacia Pub Date : 2022-12-31 DOI:10.53519/analesranf.2022.88.04.04
Montserrat Colilla Nieto
{"title":"Advanced nanoformulations against bacterial infection","authors":"Montserrat Colilla Nieto","doi":"10.53519/analesranf.2022.88.04.04","DOIUrl":null,"url":null,"abstract":"Nowadays, antibiotics remain the cornerstone in the treatment of bacterial infections. However, in recent decades, bacteria have developed defense mechanisms that make them highly resistant to the existing antibiotics, leaving us vulnerable to infection. The World Health Organization warns that bacterial resistance constitutes a serious threat to humanity at global level and that there is an urgent need of developing new antibacterial agents. Nanotechnology has entered into this scenario by providing novel tools for the treatment of numerous pathologies, highlighting cancer. Nanomedicine brings up the opportunity to address different diseases using drug nanocarriers that can be specifically directed to the therapeutic target, increasing the efficacy of the treatment and reducing the side effects. This entrance speech focuses on mesoporous silica nanoparticles, whose unique properties and enormous versatility allow the design of multiple nanosystems to treat bacterial infections. Its ability to specifically target bacteria and/or biofilm, release different drugs in a controlled manner and/or in a smart fashion, i.e. in response to certain stimuli, and incorporate therapeutic cations for combined therapies, envision the development of advanced nanoformulations that could revolutionize the fight against bacterial infection.\n\nKeywords: Nanomedicine; bacterial infection; targeted therapy; combined therapy; mesoporous silica nanoparticles; controlled drug delivery; antibiotics; metal ions","PeriodicalId":50795,"journal":{"name":"Anales De La Real Academia Nacional De Farmacia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales De La Real Academia Nacional De Farmacia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53519/analesranf.2022.88.04.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Nowadays, antibiotics remain the cornerstone in the treatment of bacterial infections. However, in recent decades, bacteria have developed defense mechanisms that make them highly resistant to the existing antibiotics, leaving us vulnerable to infection. The World Health Organization warns that bacterial resistance constitutes a serious threat to humanity at global level and that there is an urgent need of developing new antibacterial agents. Nanotechnology has entered into this scenario by providing novel tools for the treatment of numerous pathologies, highlighting cancer. Nanomedicine brings up the opportunity to address different diseases using drug nanocarriers that can be specifically directed to the therapeutic target, increasing the efficacy of the treatment and reducing the side effects. This entrance speech focuses on mesoporous silica nanoparticles, whose unique properties and enormous versatility allow the design of multiple nanosystems to treat bacterial infections. Its ability to specifically target bacteria and/or biofilm, release different drugs in a controlled manner and/or in a smart fashion, i.e. in response to certain stimuli, and incorporate therapeutic cations for combined therapies, envision the development of advanced nanoformulations that could revolutionize the fight against bacterial infection. Keywords: Nanomedicine; bacterial infection; targeted therapy; combined therapy; mesoporous silica nanoparticles; controlled drug delivery; antibiotics; metal ions
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗细菌感染的先进纳米配方
如今,抗生素仍然是治疗细菌感染的基石。然而,近几十年来,细菌已经发展出了防御机制,使它们对现有的抗生素具有高度耐药性,使我们容易受到感染。世界卫生组织警告说,细菌耐药性在全球范围内对人类构成严重威胁,迫切需要开发新的抗菌剂。纳米技术通过提供治疗多种病理的新工具,特别是癌症,进入了这一领域。纳米医学提供了利用药物纳米载体来治疗不同疾病的机会,这些药物纳米载体可以专门针对治疗靶点,提高治疗效果并减少副作用。本次演讲的重点是介孔二氧化硅纳米颗粒,其独特的性质和巨大的多功能性允许设计多种纳米系统来治疗细菌感染。它能够专门针对细菌和/或生物膜,以受控的方式和/或以智能的方式释放不同的药物,即响应某些刺激,并结合治疗阳离子进行联合治疗,展望先进纳米制剂的发展,这可能会彻底改变对抗细菌感染的斗争。关键词:纳米;细菌感染;靶向治疗;综合治疗;介孔二氧化硅纳米颗粒;控制给药;抗生素;金属离子
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.13
自引率
0.00%
发文量
7
期刊介绍: The Anales de la Real Academia Nacional de Farmacia� embraces all aspects of pharmaceutical sciences and is a quarterly journal that publishes basic and applied research on pharmaceutical sciences and related areas. It is a medium for reporting selected original and significant contributions to new pharmaceutical knowledge.
期刊最新文献
Therapeutic repositioning: importance of new therapeutic indications approved for old medicines The mRNA COVID 19 vaccine: More than a drug? Detection and management of a case of drug-resistant hypertension Galenic development of a capsule containing rosuvastatin, repaglinide, and olmesartan mini-tablets for the treatment of metabolic syndrome Novel drugs recently authorized by ema and fda (Q2, 2024)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1